Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Quantification of Immune Cells in Women Using Contraception (CHIC II)

NCT01873170 · View on ClinicalTrials.gov ↗

Study Summary

This study is being done to understand if using birth control causes changes in the immune cells within the reproductive tract (including the cervix and the lining of the uterus) of healthy women. Immune cells are important because they help prevent infections from starting and help fight infections that have started. Immune cells are also the type of cells that HIV (human immunodeficiency virus) infects so understanding more about them will help to better understand how to prevent the spread of HIV. Immune cells will be studied from the reproductive tract of women who want to start using one of the following contraceptives: an oral contraceptive pill (COC), Depo-Provera (DMPA), the levonorgestrel IUD (Mirena®), the copper IUD (ParaGard®), or the etonogestrel subdermal implant (Nexplanon®).Immune cells will also be studied from the reproductive tract of women who are not using birth control and who are not at risk of pregnancy for comparison.

Interventions

  • DRUG levonorgestrel exposure
  • DRUG DMPA exposure
  • DRUG etonogestrel exposure
  • DEVICE IUD insertion
  • DEVICE subdermal contraceptive implant insertion

Study Locations (1)

Pennsylvania

  • Center for Family Planning Research — Pittsburgh

Trial Details

FieldValue
Enrollment Target 326 participants
Start Date 2013-08
Est. Completion 2020-10

Sponsor

University of Pittsburgh

1,082 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01873170

The ClinicalTrials.gov registry entry for NCT01873170 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,082 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 5 interventions — of which levonorgestrel exposure is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01873170 reports 1 study location spanning 1 distinct geographic area — top geographies include Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01873170 about?

NCT01873170 is a clinical study titled "Quantification of Immune Cells in Women Using Contraception (CHIC II)". This study is being done to understand if using birth control causes changes in the immune cells within the reproductive tract (including the cervix and the lining of the uterus) of healthy women. Immune cells are important because they help prevent infections from starting and help fight infections...

What is the current status of trial NCT01873170?

This trial is currently completed. The enrollment target is 326 participants. The study started on 2013-08. Estimated completion is 2020-10.

What conditions does trial NCT01873170 study?

This clinical trial studies the following conditions: HIV, Contraception, Immune Cells (Mucosal and Systemic). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01873170?

The interventions under investigation include: levonorgestrel exposure (DRUG), DMPA exposure (DRUG), etonogestrel exposure (DRUG), IUD insertion (DEVICE), subdermal contraceptive implant insertion (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01873170?

This trial is sponsored by University of Pittsburgh, which has 1,082 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01873170 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial